Shenzhen Neptunus Bioengineering Co Ltd (000078) - Total Liabilities
Based on the latest financial reports, Shenzhen Neptunus Bioengineering Co Ltd (000078) has total liabilities worth CN¥24.43 Billion CNY (≈ $3.58 Billion USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Shenzhen Neptunus Bioengineering Co Ltd cash flow conversion to assess how effectively this company generates cash.
Shenzhen Neptunus Bioengineering Co Ltd - Total Liabilities Trend (1995–2024)
This chart illustrates how Shenzhen Neptunus Bioengineering Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Shenzhen Neptunus Bioengineering Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Shenzhen Neptunus Bioengineering Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shenzhen Neptunus Bioengineering Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suzhou Jinfu New Material Co
SHE:300128
|
China | CN¥2.60 Billion |
|
Simply Good Foods Co
NASDAQ:SMPL
|
USA | $716.51 Million |
|
Strait Innovation Internet Co Ltd
SHE:300300
|
China | CN¥833.90 Million |
|
Rush Enterprises B Inc
NASDAQ:RUSHB
|
USA | $2.20 Billion |
|
Tibet GaoZheng Explosive Co Ltd
SHE:002827
|
China | CN¥-1.28 Billion |
|
Tianjin Ringpu Bio Tech
SHE:300119
|
China | CN¥2.54 Billion |
|
Power HF Co Ltd
SHG:605100
|
China | CN¥455.28 Million |
|
IRSA Inversiones y Representaciones SA
BA:IRSA
|
Argentina | AR$2.22 Trillion |
Liability Composition Analysis (1995–2024)
This chart breaks down Shenzhen Neptunus Bioengineering Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Shenzhen Neptunus Bioengineering Co Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 13.41 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.90 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shenzhen Neptunus Bioengineering Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shenzhen Neptunus Bioengineering Co Ltd (1995–2024)
The table below shows the annual total liabilities of Shenzhen Neptunus Bioengineering Co Ltd from 1995 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥25.95 Billion ≈ $3.80 Billion |
-7.59% |
| 2023-12-31 | CN¥28.09 Billion ≈ $4.11 Billion |
-6.82% |
| 2022-12-31 | CN¥30.14 Billion ≈ $4.41 Billion |
-0.51% |
| 2021-12-31 | CN¥30.30 Billion ≈ $4.43 Billion |
-6.00% |
| 2020-12-31 | CN¥32.23 Billion ≈ $4.72 Billion |
-3.26% |
| 2019-12-31 | CN¥33.32 Billion ≈ $4.88 Billion |
-1.92% |
| 2018-12-31 | CN¥33.97 Billion ≈ $4.97 Billion |
+39.25% |
| 2017-12-31 | CN¥24.39 Billion ≈ $3.57 Billion |
+126.22% |
| 2016-12-31 | CN¥10.78 Billion ≈ $1.58 Billion |
+1.55% |
| 2015-12-31 | CN¥10.62 Billion ≈ $1.55 Billion |
+35.29% |
| 2014-12-31 | CN¥7.85 Billion ≈ $1.15 Billion |
+28.02% |
| 2013-12-31 | CN¥6.13 Billion ≈ $897.19 Million |
+27.56% |
| 2012-12-31 | CN¥4.81 Billion ≈ $703.35 Million |
+24.38% |
| 2011-12-31 | CN¥3.86 Billion ≈ $565.47 Million |
+19.08% |
| 2010-12-31 | CN¥3.25 Billion ≈ $474.87 Million |
+31.27% |
| 2009-12-31 | CN¥2.47 Billion ≈ $361.76 Million |
+23.81% |
| 2008-12-31 | CN¥2.00 Billion ≈ $292.19 Million |
-9.97% |
| 2007-12-31 | CN¥2.22 Billion ≈ $324.56 Million |
-16.42% |
| 2006-12-31 | CN¥2.65 Billion ≈ $388.31 Million |
-16.58% |
| 2005-12-31 | CN¥3.18 Billion ≈ $465.46 Million |
+39.76% |
| 2004-12-31 | CN¥2.28 Billion ≈ $333.03 Million |
-11.99% |
| 2003-12-31 | CN¥2.59 Billion ≈ $378.42 Million |
+89.30% |
| 2002-12-31 | CN¥1.37 Billion ≈ $199.91 Million |
+27.81% |
| 2001-12-31 | CN¥1.07 Billion ≈ $156.41 Million |
+68.71% |
| 2000-12-31 | CN¥633.55 Million ≈ $92.71 Million |
+45.11% |
| 1999-12-31 | CN¥436.59 Million ≈ $63.89 Million |
+725.49% |
| 1998-12-31 | CN¥52.89 Million ≈ $7.74 Million |
-39.90% |
| 1997-12-31 | CN¥88.00 Million ≈ $12.88 Million |
+31.62% |
| 1996-12-31 | CN¥66.86 Million ≈ $9.78 Million |
+120.11% |
| 1995-12-31 | CN¥30.37 Million ≈ $4.44 Million |
-- |
About Shenzhen Neptunus Bioengineering Co Ltd
Shenzhen Neptunus Bioengineering Co., Ltd. engages in the research and development, production, and sale of Chinese patent medicines, infusion products, and western medicine preparations in China. The company provides oryzanol tablets, chlorpheniramine maleate tablets, estazolam tablets, and rifampicin capsules, as well as technical support for generic drug quality consistency evaluation and othe… Read more